A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

• Autors principals: Roland Kratzer (Autor), Benoît Sansas (Autor), Karine Lélu (Autor), Alexei Evlachev (Autor), Doris Schmitt (Autor), Nathalie Silvestre (Autor), Geneviève Inchauspé (Autor), Perrine Martin (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2018-06-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Pre-clinical models mimicking persistent hepatitis B virus (HBV) expression are seldom, do not capture all features of a human chronic infection and due to their complexity, are subject to variability. We report a meta-analysis of seven experiments performed with TG1050, an HBV-targeted immunotherap...